Drug Trial Radar · NCT06555068
A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
528
Planned (sponsor's estimate)
Start
Aug 12, 2024
Primary completion
Dec 2027
Study completion Aug 2028
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the safety, PK and efficacy of HRS-6209 in Combination with Fulvestrant, Letrozole, HRS-8080, HRS-1358 ,or HRS-9813 and HRS-8080,or letrozole and trastuzumab, with or without pertuzumab, or HRS-4508 and letrozole, with or without trastuzumab and/or pertuzumab, for advanced unresectable or metastatic breast cancer or HRS-9813 as monotherapy in Patients with Advanced Solid Tumors
Conditions
- Advanced Unresectable or Metastatic Breast Cancer
- Advanced Solid Tumors
Interventions
HRS-6209 in Combination with FulvestrantDrug
HRS-6209 in Combination with Fulvestrant
HRS-6209 in Combination with HRS-1358Drug
HRS-6209 in Combination with HRS-1358
HRS-6209 in Combination with LetrozoleDrug
HRS-6209 in Combination with Letrozole
HRS-6209 in Combination with HRS-8080Drug
HRS-6209 in Combination with HRS-8080
HRS-6209 in Combination with HRS-1358Drug
HRS-6209 in Combination with HRS-1358
HRS-6209 in Combination with HRS-9813 and LetrozoleDrug
HRS-6209 in Combination with HRS-9813 and Letrozole
HRS-6209 in Combination with HRS-9813 and HRS-8080Drug
HRS-6209 in Combination with HRS-9813 and HRS-8080
HRS-6209 in Combination with letrozole and trastuzumabDrug
HRS-6209 in Combination with letrozole and trastuzumab
HRS-6209 in Combination with letrozole and trastuzumab and pertuzumabDrug
HRS-6209 in Combination with letrozole and trastuzumab and pertuzumab
HRS-6209 in Combination HRS-4508 and letrozoleDrug
HRS-6209 in Combination HRS-4508 and letrozole
HRS-6209 in Combination HRS-4508 and letrozole and trastuzumab and pertuzumabDrug
HRS-6209 in Combination HRS-4508 and letrozole and trastuzumab and pertuzumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLT (dose-limiting toxicity)-Stage I (dose exploration)Time frame: 28 days after the first dose
- MTD (maximum tolerated dose) -Stage I (dose exploration)Time frame: 28 days after the first dose
- RP2D (recommended phase II dose) -Stage I (dose exploration)Time frame: 28 days after the first dose
- (Serious) AEs-Stage I (dose exploration)Time frame: every week in Cycle 1 (28 days after the first dose), every 2 weeks in Cycle 2 (28 days after the second dose), every 4 weeks from Cycle 3 and thereafter (28 days after each dose), lasting about one year
- ORR ( objective response rate )-Stage II (efficacy expansion)Time frame: every 8 weeks lasting about one year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.